LoginGet started
Picture of Heidelberg Pharma AG logo

HPHA — Heidelberg Pharma AG Income Statement

0.000.00%
de flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock
Balance sheetIncome statementCashflow
Subscribe to view all data

Annual income statement for Heidelberg Pharma AG, fiscal year end - November 30th, EUR millions except per share, conversion factor applied.

2019
November 30th
2020
November 30th
2021
November 30th
2022
November 30th
2023
November 30th
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue7.318.491.7518.59.86
Cost of Revenue
Gross Profit3.572.89-2.9613.86.61
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses17.526.827.435.731.1
Operating Profit-10.1-18.3-25.6-17.2-21.2
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-10.1-18.4-26.1-17.8-20.3
Provision for Income Taxes
Net Income After Taxes-10.1-18.4-26.1-19.7-20.3
Net Income Before Extraordinary Items
Net Income-10.1-18.4-26.1-19.7-20.3
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-10.1-18.4-26.1-19.7-20.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.365-0.611-0.81-0.53-0.43
Dividends per Share